Results 31 to 40 of about 15,268 (219)

Synthesis of C-5" and C-6"-modified α-GalCer analogues as iNKT-cell agonists [PDF]

, 2015
Alpha-Galactosyl Ceramide (α-GalCer) is a prototypical synthetic ligand of invariant natural killer T (iNKT) cells. Upon presentation by the MHC class I-like molecule CD1d, this glycolipid stimulates iNKT cells to secrete a vast amount of both pro ...
ASPESLAGH, SANDRINE, Elewaut, Dirk, Guillaume, Joren, Pauwels, Nora, Van Calenbergh, Serge, Zajonc, Dirk   +5 more
core   +1 more source

MAIT cells come to the rescue in cancer immunotherapy? [PDF]

, 2020
Recent progress in immunobiology has led to the observation that, among cells classically categorized as the typical representatives of the adaptive immune system, i.e., T cells, some possess the phenotype of innate cells.
Elewaut, Dirk, Venken, Koen, Łukasik, Zuzanna   +2 more
core   +2 more sources

De novo fatty-acid synthesis protects invariant NKT cells from cell death, thereby promoting their homeostasis and pathogenic roles in airway hyperresponsiveness

eLife, 2023
Invariant natural-killer T (iNKT) cells play pathogenic roles in allergic asthma in murine models and possibly also humans. While many studies show that the development and functions of innate and adaptive immune cells depend on their metabolic state ...
Jaemoon Koh, Yeon Duk Woo, Hyun Jung Yoo, Jun-Pyo Choi, Sae Hoon Kim, Yoon-Seok Chang, Kyeong Cheon Jung, Ji Hyung Kim, Yoon Kyung Jeon, Hye Young Kim, Doo Hyun Chung   +10 more
doaj   +1 more source

A Potent CD1d-binding Glycolipid for iNKT-Cell-based Therapy Against Human Breast Cancer [PDF]

, 2019
Background/Aim: Invariant natural killer T-cells (iNKT) stimulated by CD1d-binding glycolipids have been shown to exert antitumor effects by a number of studies in a mouse model.
Brutkiewicz, Randy R., Liu, Jianyun, Seki, Toshiyuki, Tsuji, Moriya   +3 more
core   +1 more source

iNKT and MAIT Cell Alterations in Diabetes [PDF]

Frontiers in Immunology, 2015
Type 1 diabetes (T1D) and type 2 diabetes (T2D) are multifactorial diseases with different etiologies in which chronic inflammation takes place. Defects in invariant natural killer T (iNKT) cell populations have been reported in both T1D and T2D patients, mouse models and our recent study revealed mucosal-associated invariant T (MAIT) cell defects in ...
Magalhaes, Isabelle, Kiaf, Badr, Lehuen, Agnès   +2 more
openaire   +4 more sources

Altered thymic differentiation and modulation of arthritis by invariant NKT cells expressing mutant ZAP70 [PDF]

, 2018
Various subsets of invariant natural killer T (iNKT) cells with different cytokine productions develop in the mouse thymus, but the factors driving their differentiation remain unclear.
A Hutloff, AK Stanic, B San Luis, BB Au-Yeung, BB Au-Yeung, CQ Chu, D Davidson, DG Pellicci, DG Pellicci, DG Wei, DI Godfrey, EJ Wherry, F Scheuplein, F Scheuplein, FW McNab, G Anderson, G Fu, G Kollias, G Seumois, H Georgiev, H Watarai, HS Azzam, I Engel, I Engel, J Henao-Mejia, J Novak, J Zikherman, JL Matsuda, JL Matsuda, JM Mason, K Benlagha, K Hirota, K Oleinika, K Yamamoto, L Brossay, L Linsen, LH Mason, LM D'Cruz, M Cruz Tleugabulova, M Gaya, M Guma, M Hashimoto, M Kronenberg, M Zhu, MA Weinreich, MB Drennan, MC Leite-De-Moraes, MC Leite-De-Moraes, MI Zimmer, MP Seiler, N Bottini, N Sakaguchi, NA Nagarajan, R Genolet, RJ Martinez, S Akbulut, S Jung, S Picelli, S Sidobre, SE Levin, TN Newman, V Cerundolo, V Sivakumar, WY Lee, X Li, YJ Lee, YL Chiu   +66 more
core   +4 more sources

Differential Control of iNKT Cell Effector Lineage Differentiation by the Forkhead Box Protein O1 (Foxo1) Transcription Factor

Frontiers in Immunology, 2019
The invariant NKT (iNKT) cells recognize glycolipid antigens presented by the non-classical MHC like molecule CD1d. They represent an innate T-cell lineage with the ability to rapidly produce a variety of cytokines in response to agonist stimulation to ...
Huishan Tao, Huishan Tao, Lei Li, Lei Li, Ying Gao, Zehua Wang, Xiao-Ping Zhong, Xiao-Ping Zhong, Xiao-Ping Zhong   +8 more
doaj   +1 more source

Engineered Stem Cells Provide Cancer-Killing iNKT Cells [PDF]

Cell Stem Cell, 2019
Invariant natural killer T (iNKT) cells have been tested for their potential use in cancer immune therapy, but their low frequency has limited their use. In this issue, Zhu and colleagues propose to overcome this by engineering hematopoietic stem cells (HSCs) to provide a continual source of iNKT cells. (Zhu et al., 2019).
Mallory Paynich, Murray, Mitchell, Kronenberg   +1 more
openaire   +2 more sources

The response of CD1d-restricted invariant NKT cells to microbial pathogens and their products

Frontiers in Immunology, 2015
Invariant natural killer T (iNKT) cells become activated during a wide variety of infections. This includes organisms lacking cognate CD1d-binding glycolipid antigens recognized by the semi-invariant T cell receptor of iNKT cells. Additional studies have
Luc eVan Kaer, Vrajesh eParekh, Lan eWu
doaj   +1 more source

Immunoregulation by iNKT Cells

YAKUGAKU ZASSHI, 2009
NKT cells are defined as cells co-expressing of the natural killer receptors such as NK1.1 or NKR-P1A (CD161) and a T cell receptor (TCR). Although NK1.1(+) TCR(+) lymphocytes are heterogeneous, we focus on two distinct T cell subsets express invariant T cell receptor alpha chains, Valpha14-Jalpha18(Valpha14i) and Valpha19-Jalpha33(Valpha19i ...
openaire   +4 more sources